Omalizumab decreases IgE production in patients with allergic (IgE‐mediated) asthma; PKPD analysis of a biomarker, total IgE

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Omalizumab is a humanized anti‐IgE monoclonal antibody that binds and captures circulating IgE, preventing interaction with receptors on mast cells and basophils, thereby interrupting the allergic cascade. It has a well‐characterized efficacy and safety pro...

Full description

Saved in:
Bibliographic Details
Published in:British journal of clinical pharmacology 2011-08, Vol.72 (2), p.306-320
Main Authors: Lowe, Philip J., Renard, Didier
Format: Article
Language:English
Subjects:
Adolescent
Adult
Age
Aged
Anti-Asthmatic Agents - pharmacokinetics
Anti-Asthmatic Agents - pharmacology
Antibodies, Anti-Idiotypic - pharmacology
Antibodies, Monoclonal, Humanized - pharmacokinetics
Antibodies, Monoclonal, Humanized - pharmacology
asthma
Asthma - immunology
Basophils
Biological and medical sciences
Biomarkers - blood
Child
Child, Preschool
Chronic obstructive pulmonary disease, asthma
Female
Humans
IgE
Immunoglobulin E - blood
Immunoglobulin E - metabolism
Male
Mast Cells
Medical sciences
Middle Aged
Models, Theoretical
Omalizumab
pharmacodynamic
pharmacokinetic
Pharmacology. Drug treatments
Pneumology
Randomized Controlled Trials as Topic
Uropharmacology Themed Section
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!